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ABSTRACT
Title: Identification and Role of the MTA1 Complex in Small Intestinal Carcinoid Malignancy
Authors: M Zikusoka, M Kidd, G Eick, IM Modlin
Background: Carcinoid tumors are rare tumors that, despite advances in medical research, have
remained enigmatic. Carcinoid tumors can be categorized using gross pathological, histological,
and biochemical profiles. While of some utility, this classification method fails to enable accurate
determination of malignant potential. Incorporation of molecular analysis of carcinoids will create
a paradigm shift in classification. To this end, high throughput technologies such as Quantitative
RT PCR, Tissue Microarray, and cDNA Microarray will facilitate such changes.
In our investigations, cDNA microarray analysis identified Metastasis-associated protein-1
(MTA1), Histone Deacetylase 2 (HDAC2), and aberrant transcriptional regulation as factors
involved in the molecular pathogenesis of SICs. HDAC2 mediates histone deacetylation,
resulting in chromatin remodeling and transcriptional repression while MTA1, found in complex
with HDAC2, is not only a mediator of transcriptional repression, but also of cell growth and
motility. These proteins, as mediators of epigenetic processes, are markers of malignancy in
gastric, breast, colorectal, and hematological malignancies. HER2 has been implicated in MTA1
upregulation in the breast cancer model. Analysis of HDAC2 and MTA1 expression and their
roles in SIC malignancy could potentially alter SIC classification and lead to the investigation of
anti-epigenetic cancer strategies such as HDAC inhibitors.
Hypothesis: MTA1 and HDAC2 (MTA1/HDAC2 complex), involved in transcriptional
regulation are both markers of SIC malignancy and function in SIC pathogenesis. HER2 mediates
MTA1 upregulation in SICs, as in breast tumors. HER2, ER, and CpG island methylation may be
involved in SIC tumorigenesis by regulating MTA1 expression.
Methods: The gene expression profile of eight (8) GI carcinoid samples was analyzed using
Afffymetrix ™ Gene Chip ® technology. Transcript expression of HDAC2, MTA1, HER2, ER2,
and Trefoil Factor 1 (TFF1) was examined in normal mucosa and SIC samples using Quantitative
RT-PCR. Protein expression of HDAC2, MTA1, HER2, ER2, and TFF1 was measured on a
carcinoid tissue microarray containing 55 SIC tumor samples with matched normal mucosa.
HDAC activity was quantified directly through an enzymatic assay and Trichostatin A (TSA)
inhibition and indirectly by analysis of histone acetylation on TMA. MTA1 upregulation in SICs
was explored through analysis of HER2 gene and protein expression patterns and of the MTA1
promoter region.
Results: Affymetrix GeneChip and Ingenuity Pathway analysis identified aberrant transcriptional
repression mediated by MTA1 and HDAC2 as a principal pathway in SICs. Q-RT-PCR: MTA1:

nml-1.68±0.16, primary- 3.58±1.5*, mets-5.96±2.4#; HDAC2: nml-0.07±0.02, primary-2.0±0.8&, mets4.1±0.6&; HER2: nml-2.28±0.51, primary-1.02±0.23*, mets-0.8±0.39#; ERα: nml-0.49±0.19, primary5.71±3.1#, mets-3.01±1.4#; TFF1: nml-0.86±0.21, primary- 0.005±0.002*, mets-0.0059±0.0018*. TMA
analysis: MTA1: nml-3±1 local-75±12#, disseminated-78±1#; HDAC2: nml-524± 81. local-712±101#,
disseminated-762±105#; HER2: nml- 10±1, local-9±1NS, disseminated-6±0.5NS; ERα: nml- 11±0.5, local10.1±1NS, disseminated-12±0.5NS; TFF1: nml- 98, local-83±5NS, disseminated-75±4NS.HDAC activity in
SICs: nml- 0.08, nml with TSA- 0.04, SIC- 0.32, SIC with TSA- 0.081. Indirect HDAC activity
assessment through TMA: nml- 757±116, local- 502±121#, disseminated- 523±112#.Ratio of
acetylated to unacetylated H2B: nml- 1.74, SIC-1.43. (*p=0.05, #p<0.05, NS=not significant)

Analysis of the MTA1 promoter region revealed c-Myc, c-Fos/c-Jun, c-Myc, SP1 responsive
elements as well as CpG islands. Attempts to amplify the MTA1 promoter region were
unsuccessful.
Conclusion: HDAC2 and MTA1 are functional markers of SIC malignancy. Both transcript and
protein expression increased as tissue progressed from normal SI mucosa to primary SIC to
metastatic SIC tissue. Involved in epigenetic processes, these proteins and their respective
pathways may be potential therapeutic targets of HDAC inhibitors. Low HER2 expression and a
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lack of correlation with MTA1 expression suggests other mechanisms of MTA1 upregulation in
SIC tissue. These may include c-Myc, c-Fos/c-Jun, c-Myb, SP1, and CpG island (de)methylation.
Further investigations will provide more information regarding modes of MTA1 upregulation in
SIC. Overall, epigenetic modulation via the MTA1/HDAC2 complex may be of importance in
SIC tumorgenesis and molecular analysis may be a means of enhancing SIC classification with a
view to facilitating improved diagnosis, prognostication, and therapeutic strategy.
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1. Introduction
Carcinoid tumors are rare tumor entities that, despite much advancement in
medical research, have remained enigmatic. Previously considered to be benign relative
to adenocarcinomas, many cases have shown, to the contrary, that carcinoid tumors have
the potential to behave rather aggressively, resulting in a complicated disease course.
Comprising 67% of all diagnosed carcinoid tumors(1), gastrointestinal (GI) carcinoids
occur most frequently in the small intestine, the rectum, and the stomach. An examination
of their 5-year survival rate- 60.5%, 88.3%, and 63.0%, respectively(1)- suggests points
of divergence in their molecular biology and, concomitantly, in their disease course. With
their very own unique biological and clinical characteristics, GI carcinoid tumors deserve
closer scrutiny and further elucidation of their nature.
Past methods of carcinoid tumor classification have incorporated gross
pathological, histological, embryological, and biochemical criteria. While of some utility,
these methods fail to provide a means with which to determine malignant potential which
could facilitate prognostication. In addition, the exploration of the molecular biology of
carcinoid tumors may lead to the targeted design of therapeutic approaches.
This thesis explores molecular methods of small intestinal carcinoid (SIC)
classification while elucidating potential molecular pathways involved in their
tumorigenesis. In our investigations, we have employed cDNA Microarray, Pathway
Analysis, Q-RT-PCR, Tissue Microarray, and Enzymatic Assays in order to further
define the molecular nature of SICs.
Our preliminary gene expression profile data [FIGURE 2] has led to a focus on
histone deacetylase 2 (HDAC2) and metastases associated protein-1 (MTA1). Found in

7

complex, these two proteins are major components of epigenetic processes. Epigenetics is
a field that involves the study of changes in gene function that are mitotically and/or
meiotically heritable. These changes do not involve alterations in nuclear DNA sequence
(2, 3). The major modes of epigenetic modulation include methylation and histone
(de)acetylation. HDAC2 is a mediator of histone deacetylation through a hydrolytic
process that induces chromatin remodeling. Such alterations result in a transcriptionally
inactive DNA conformation (4). Increases in HDAC2 expression levels have been noted
in gastric(5) and colorectal carcinomas(6). MTA1, found in complex with HDAC2 (7), is
involved not only in transcriptional repression (8), but has been implicated in cellular
growth (9) and motility (10). Increased levels of MTA1 have been found in breast (11),
hepatocellular (12), esophageal (13), gastric, and colorectal (14) carcinoma patients with
evidence of metastasis or aggressive disease course.
We hypothesize that aberrant transcriptional regulation, mediated by the
MTA1/HDAC2 complex, may be central to SIC tumorigenesis and the development of
metastatic qualities. Thusly, MTA1 and HDAC2 have functional roles in SIC
development and may aid in the classification of SIC subtypes, thus facilitating improved
diagnosis, prognostication and therapeutic strategy.

2. A Brief Overview of Gastrointestinal Carcinoids
2a. Early History
Prior to Siegfried Oberndorfer’s 1907 introduction of the term karzinoid (15)
(carcinoma-like), there were a number of early reports of these unique tumor entities. In
1867, T. Langhans wrote of a firm, mushroom-shaped submucosal tumor that was
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histologically described as poorly differentiated glandular tissue arranged in ‘nests’ with
a rich, thick fibrous stroma (16). An 1888 autopsy by O. Lubarsch revealed multiple
similar ileal tumors, but he hesitated to call them true carcinomas (17). In 1890, W.B.
Ransom also reported ileal tumors with similarly described unique characteristics, but in
addition, emphasized the associated symptoms which included diarrhea and wheezing,
thus the first documentation of carcinoid syndrome (18). In 1907, Oberndorfer described
the small intestinal tumors as follows: “mostly small and multiple, tend to be surrounded
by undifferentiated tissues, have the potential to become invasive, do not metastasize, and
grow extremely slowly and are, therefore, of a harmless nature (15).” This benign
assessment of these tumors was later refined when further analysis led Oberndorfer to
note the malignant potential of these karzinoid tumors (19).
2b. The Enterochromaffin Cell: Cell of GI Carcinoid Origin
Distinguished by its deep yellow stain pattern upon exposure to bichromate
solutions, the enterochromaffin cell (EC), first described by R.P. Heidenhain (20) in
1896, is found in the crypts of Lieberkuhn of the GI mucosa (N. Kulchitsky 1897 (21)).
The actual term ‘enterochromaffin’ was introduced by M.C. Ciacco (22) in 1906 in order
to categorize the cells with regards to staining properties and anatomical location.
One of the earliest links between carcinoid tumors and their EC cell origin was
presented by the studies of A. Gosset and P. Masson (1914) (23). In 1948, A.B. Dawson
had developed a technique by which EC and enterochromaffin-like (ECL) cells of the
gastrointestinal tract could be stained using silver nitrate (24). Many decades later, Solcia
et al. (1969) perfected the method to differentiate EC cells with various chemical staining
techniques (including chromaffin, argentaffin, and diazonium) which were noted to react

9

specifically with 5-hydroxytryptophan (5-HTP), an EC cell-specific product (25). Further
demonstrating the EC cell-carcinoid link was the work of F. Lembeck (1953) which
biochemically confirmed the presence of 5-Hydroxytryptamine (5-HT) in an ileal
carcinoid tumor (26). [FIGURE 1]

Figure 1. Timeline of Major Events in Carcinoid History

2c. Classification
In an attempt to define carcinoid tumors, a number of classifications have been
proposed. In 1963, Williams and Sandler classified these tumors based on their putative
embryological origin (foregut, midgut, or hindgut) (27). Despite the simplicity of this
system, it became apparent that carcinoid tumors differed greatly as far as morphology,
function, and biology—rendering embryological classification to be of little utility. This
10

system, however, remained the general convention despite the fact that it proved too
imprecise and failed to convey the diverse spectrum of neoplasms with widely different
secreting products that originate from different neuroendocrine cell types (28).
In 1971, J. Soga and Y. Yakuwa introduced a histological approach to the
classification of carcinoids, describing the tumors according to their dominant growth
pattern: insular, trabecular, glandular, mixed, or undifferentiated. This system combined
histological findings, silver staining patterns, electron microscopy findings of specific
secretory granules, and routine clinical investigations such as biochemistry (5hydroxytrytophan, 5-hydroxyindole acetic acid or histamine) and clinical history with
physical findings (29). This combination served to morphologically classify tumors while
incorporating clinical parameters.
A. Pearse recognized an important cytochemical commonality between the
endocrine cells of the gut: the uptake of 5-HTP and its decarboxylation to 5-HT
(serotonin) (30). By 1968, these peptide hormone-producing cells, all of which derived
from the neural crest, were collectively called APUD (Amine Precursor Uptake and
Decarboxylation) cells (31), While Pearse and others initially suggested that APUD cells
were derived from neural crest cells, it is now generally recognized that
gastroenteropancreatic APUD cells probably arise from the endoderm (32).
Most recently, Kloppel et al. (33) presented an updated World Health
Organization system for the classification of neuroendocrine tumors of the
gastroenteropancreatic system (2004) in an attempt to improve terminology, avoid
variances in definition, and provide a uniform basis for assessment. In brief, three main
categories were created: well-differentiated neuroendocrine tumors (NETs), well-
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differentiated neuroendocrine carcinomas (NECs), and poorly differentiated NECs. The
term ‘carcinoid’ was retained to refer to gastrointestinal NETs that are well-differentiated
neuroendocrine tumors. Overall, the goal was to provide a prognostically relevant
classification system that assessed tumors according to size, proliferative activity,
angioinvasion, organ invasion, metastases, hormonal activity, and clinical syndromes.
2d. Epidemiology
Gastrointestinal carcinoids fall under a broader category of tumorsGastroenteropancreatic Neuroendocrine Tumors (GEP-NETs). This classification
includes pancreatic tumors such as insulinomas and gastrinomas. Uniting these tumor
types is their derivation from cells of neuroendocrine origin and the secretion of
chromogranin A (34) (CgA), synapotophysin (35), and neuron-specific enolase (36)
(NSE). Specifically examining carcinoids, multiple epidemiological analyses have been
undertaken to further our understanding of carcinoid incidence, distribution, and survival.
Despite the rarity of these tumors, multiple epidemiological analyses have been published
using either post-mortem evaluation (37) or, more recently, population registries (1, 38,
39).
In 1975, Godwin (38) provided a fundamental contribution in his evaluation of
carcinoid tumor incidence, distribution, and survival in the United States. The survey
analyzed 2,837 carcinoid cases registered between 1950 and 1971. This body of work
examined a heterogeneous population, noting higher age-adjusted incidence rates for
black males, with the exception of bronchopulmonary carcinoids, and 5-year survival
rates as high as 99% in the appendix and as low as 33% in the sigmoid colon.
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Most recently, Modlin et al. (1) (2003) provided a 5-decade analysis (1950-1999)
of carcinoid tumors (n=13,715). Overall, carcinoid tumor incidence appears to have
increased with gastrointestinal (GI) carcinoids representing the largest group (67.5%). GI
carcinoids are found most frequently in the small intestinal (41.8%), rectum (27.4%), and
stomach (8.7%). Nonlocalized disease was most frequently found in cecal (81.5-83.2%)
and pancreatic (71.9-81.3%) cases. While the overall 5-year survival rate for carcinoid
neoplasms was 67.2%, patients with rectal, bronchopulmonary, and appendiceal
carcinoids had the highest 5-year survival rates (88.3%, 73.5%, and 71.0%). These
numbers refute the popular notion that these tumors are relatively homogeneous and
benign in both nature and clinical course. Considering race, blacks and Asians had a
disproportionate representation in rectal carcinoids, suggesting the potential role of
genetic predisposition for this tumor subtype. The overall apparent increase in carcinoid
incidence over the 50-year survey may be attributed to increased knowledge, the
evolution of diagnostic and imaging modalities, and the increase in endoscopic
investigations.
2e. Clinical Presentation and Complications
In 1890, W.B. Ransom provided the first account of carcinoid syndrome in a
patient with ileal tumors and hepatic metastases (18). The symptomatology associated
with carcinoid disease may be due to tumor mass effects, carcinoid-associated fibrosis,
and syndrome symptoms such as cutaneous flushing, diarrhea, and bronchospasm caused
by biologically active products secreted by the tumor into the bloodstream (40).
Unfortunately, only 10% of patients may present with carcinoid syndrome (37), thus
presenting a diagnostic challenge for clinicians. This condition is often mistaken for
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menopause or Irritable Bowel Syndrome, thus delaying diagnosis and appropriate
treatment (40).
Much of carcinoid symptomatology is attributed to the release of serotonin (5HT) from the carcinoid tumor cells. Serotonin was first isolated and described by M.
Rapport in 1948 (41). This biologically active substance was extracted from EC cells in
1952 (42). The following year, F. Lembeck confirmed the presence of 5-HT in an ileal
carcinoid (26). These findings would later lead to a biochemical means of carcinoid
diagnosis through the examination of patient serum.
A major complication of carcinoid disease is the development of fibrosis. In 1931,
A.J. Scholte first reported the cardiac manifestations of carcinoid disease in a patient with
an ileal tumor, symptoms of congestive heart failure, and thickened tricuspid valves and
right atrial endocardium on autopsy (43). Thirty years later, C. Moertel drew the link
between carcinoids and fibrosis (44).
Fibrotic changes are not only found in the heart. They may also occur in the
bronchopulmonary system (45), the mesentery, and the retroperitoneum, causing
complications such as bowel obstruction (46) and hydronephrosis secondary to stenosis
of the ureters (47). The exact mechanism of this fibroblastic process in the mesentery
does not appear to involve serotonin as its levels do not seem to correlate with the
development of fibrotic disease (48). In addition, serotonin alone does not stimulate
fibroblast growth according to in vitro studies (49). On the contrary, increased 5hydroxyindoleacetic acid (5-HIAA), a product of serotonin degradation, correlates with
increased incidence of carcinoid cardiac involvement (50, 51).
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The pathogenesis of fibrotic processes in carcinoid disease involves Transforming
Growth Factor- Beta (TGF-β), a potent stimulator of fibroblast proliferation (52), and
Connective Tissue Growth Factor (CTGF), a downstream mediator (53). TGF-β has been
found in fibrotic cardiac carcinoid lesions (54) while CTGF has been found in excessive
amounts in the serum of carcinoid patients with fibrotic disease (55). These growth
factors may work in concert in the presentation of fibrotic complications. It is, therefore,
judicious to direct future efforts towards therapeutic mediators of these growth factors,
thus potentially halting fibrotic progression in carcinoid disease.
2f. Biochemical Diagnosis
Critical to the diagnosis of carcinoid disease is biochemical analysis. In 1954, I.H.
Page demonstrated the utility of serotonin as a plasma marker for carcinoid disease. He
also observed elevated urinary excretion of the main serotonin metabolite, 5-HIAA, in a
patient with carcinoid syndrome (56). Today, the measurement of urinary 5-HIAA over a
24-hour period is still utilized in order to provide clinicians with an estimation of tumor
activity. This however, is not as sensitive as the measurement of serum Chromogranin A
(CgA). CgA is a neuroendocrine tumor marker with elevated levels in carcinoids,
pancreatic endocrine tumors, and prostatic carcinoma (57). Its measurement provides
information regarding tumor burden (58). Both CgA and 5-HIAA, while diagnostic, are
also valuable in following the patient’s clinical course. High levels of urinary 5-HIAA,
for instance, are associated with increased risk of cardiac carcinoid disease (59) as well as
perioperative complications (60). Such information may serve as a guide to clinical
decisions.
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2g. Diagnostic Imaging
Multiple imaging modalities exist to aid in localization of carcinoid disease.
Luminal examination is facilitated by barium studies (61), enteroclysis (62), endoscopy
(63), and capsule endoscopy (64). These modalities, while useful, are not the definitive
diagnostic studies of choice.
CT and MRI will facilitate visualization of mass lesions, calcifications, and
evidence of fibrosis (radiating strands and spiculation) and have detection and sensitivity
rates of 80% (65). Neuroendocrine-specific modes such as Somatostatin Receptor
(SSTR) scintigraphy (SRS) with 111Indium labeled octreoscan (66) and 11C-5HTP PET
scan (67), can detect not only primary tumors, but also areas of metastasis and active
carcinoid activity. A recent study has shown that 11C-5HTP PET is able to detect more
lesions when compared with CT and SRS (68). These modes of imaging incorporate our
current understanding of carcinoid biology.
2h. Therapeutic Approaches
2h.i. Medical Interventions
Early attempts to relieve symptoms associated with carcinoid syndrome have
included treatment with methysergide (69), chlorpromazine (70), p-chlorophenylalanine
(71), and cyproheptadine hydrochloride (72). All of these drugs have proven effective in
decreasing diarrhea, but had little efficacy in combating flushing.
Prior to the current understanding of somatostatin receptors and their importance
in carcinoid disease, chemotherapy became a therapeutic strategy in the eradication of
carcinoid tumor disease and the relief of carcinoid-associated symptoms.
Chemotherapeutics have included monotherapies such as Actinomycin D (73), 5-
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Fluorouracil (74), Dacarbazine (73), Streptozotocin (75), and cis- Platinum (76) along
with combination chemotherapy such as cyclophosphamide with methotrexate (77) and
5-fluorouracil with streptozotocin (77). Unfortunately, none of these strategies were
successful and results were often inconsistent. The lack of success with
chemotherapeutics is likely due to the slow, indolent course of carcinoid tumor growth.
Given their mechanisms of action, these drugs are most effective in rapidly proliferating
tumor types. Overall, chemotherapeutics had an efficacy rate ranging from 7 to 40% (78).
A more sophisticated knowledge of somatostatin, its receptors, and their
association with carcinoid tumors created a complete shift in the clinician’s approach to
carcinoid syndrome. Somatostatin was first isolated by P. Brazeau (79) in 1973. This
peptide was thought to have an effect on growth hormone release through inhibition.
Later studies would reveal this hormone’s multi-functional capacity, affecting motor and
cognitive function, gastrointestinal motility, absorption in the gut, and even cell growth
and proliferation (80-82). Unfortunately, somatostatin’s potential in the alleviation of
carcinoid syndrome symptomatology is hampered by its extremely short half-life (2-4
minutes) (83). This greatly affects the utility of this hormone as a therapeutic approach to
carcinoid disease. In 1982, W. Bauer et al. (84) reported the creation of SMS-201-995
(octreotide), a potent somatostatin analogue with a half-life of 1.5 to 2 hours. Three years
later, it was used in the treatment of carcinoid disease (85). The same year (1985),
octreotide was introduced in the operating room and utilized in the successful
intervention of intraoperative carcinoid crisis (86). In 2002, SOM230 was developed as a
somatostatin analogue with receptor affinity for all somatostatin receptor sub-types (87).
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The introduction of long-acting somatostatin analogues has created a new
direction in carcinoid syndrome symptom control. Today, somatostatin analogues may be
administered subcutaneously every 6 to 12 hours (Sandostatin; Novartis, East Hanover,
NJ) or in a depot form (Sandostatin LAR; Novartis, East Hanover, NJ) every 2 weeks.
Both regimens effectively control carcinoid syndrome symptomatology in 70-80% of
patients (88, 89). Associated side effects include gallbladder stones, cardiac arrhythmias,
and endocrine abnormalities such as hypothyroidism and hypo/hyperglycemia (90).
Given the risk of gallstone formation and cholelithiasis, it is judicious for carcinoid
patients to undergo prophylactic cholecystectomy (91).
In addition to a somatostatin analogue treatment regimen, human leukocyte
interferon (HLI), interferon-alpha, and interferon-beta appear to be of utility as
demonstrated by the reduction of biochemical markers and by objective tumor shrinkage
(92-95). A serious adverse effect profile which includes myelosuppression may impede
its wide-spread use (90, 96).
2h.i.a. Radio-labeled Somatostatin Analogues
Cells expressing somatostatin receptors have the ability to internalize somatostatin and its
analogues (97). Taking advantage of this phenomenon, scientists and clinicians have
investigated the use of radiotherapy in tumors with strong express of somatostatin
receptors. 111Indium and 90Yytrium-labeled somatostatin analogues have been utilized
with variable responses. 111Indium radionuclide therapies elicited response rates between
13 and 20% (98-101) while [90Yytrium-DOTA0Tyr3] octreotide induced partial
remissions in 10 and 30% of subjects (102, 103). [177Lutetium- DOTA0Tyr3] octreotate
had more promising results with complete or partial responses in 30% of patients and
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tumor response in 48% (104, 105). Future developments in the area of radio-labeled
somatostatin analogue therapeutics may lead to effective GI carcinoid eradication.
2h.ii. Surgical Interventions
The goal of surgical intervention is the resection of the primary tumor and
reduction of tumor bulk in areas of metastases, particularly in the liver. These
interventions serve to alleviate mechanical complications such as bowel obstruction (106)
and, in many cases, relieve carcinoid-associated symptomatology (107). In surgical cases
with residual tumor, SST analogues may be given to given to effectively control the
symptoms of carcinoid syndrome (90).
Not all cases of gastrointestinal carcinoid will require laparotomy. Some, such as
gastric (subtypes I and II) and rectal carcinoids, may be amenable to endoscopic excision
approaches (108, 109). In the case of hepatic metastases, multiple options are available.
These include hepatic resection (110), radiofrequency ablation (111), and embolization
with or without cytotoxics or isotopic microspheres (111, 112). In rare cases, a hepatic
transplant (five-year survival rate of 69%) may be pursued (113, 114).
Multiple options exist for the gastrointestinal carcinoid patient. The future
direction of therapeutic approaches will be greatly aided by improvements in diagnosis
and knowledge of carcinoid tumor biology. Such developments will guide clinical
decisions and improve patient outcome.

3. Challenges in Advancement of Gastrointestinal Carcinoid Knowledge
While much has been gained in the century since Oberndorfer’s pivotal
contribution, we have yet to harness the ability to accurately characterize carcinoid
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tumors with regard to their malignant potential and clinical course. This challenge may be
surmounted by novel molecular analytic techniques. Until then, biological basis of
gastrointestinal carcinoids remains enigmatic.
3a. The Current Status of GI Carcinoid Classification
The updated World Health Organization system for the classification of
neuroendocrine tumors (NETs) of the Gastroentero-Pancreatic (GEP) system (2004),
presented by Kloppel et al.(33), serves to redefine nomenclature utilized to distinguish
between carcinoids, pancreatic endocrine tumors such as insulinomas, and other tumors
of the GEP system of neuroendocrine origin. The categories include well-differentiated
neuroendocrine tumors (NETs), well-differentiated neuroendocrine carcinomas (NECs),
and poorly differentiated NECs. Carcinoids are categorized as well-differentiated NETs.
While this system may serve to provide a basis of classification with a view to
prognostication, it still depends on traditional methods used by previous systems, namely
histology, clinical presentation, and biological activity. Despite the advances in molecular
biology and genetic analysis, we have yet to incorporate these tools into classification
methodologies.
3b. Molecular Biology and the Future of GI Carcinoid Classifiction
The future of GI carcinoid classification will rely more and more on molecular
genetic analysis. Numerous investigations have uncovered a number of molecular
alterations in GI carcinoids.
An interrogation of the molecular basis of carcinoid tumorigenesis through
Comparative Genomic Hybridization (CGH) and Microsatellite Analysis methods
highlights their heterogeneous nature and divergent developmental pathways. Differences
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include chromosomal losses or gains found strictly in the foregut versus midgut
carcinoids (115). Even among subtypes of gastric carcinoids (type I associated with
atrophic gastritis, type II associated with Zollinger-Ellison syndrome, and type III,
sporadic and the most malignant), genetic differences were observed in the loss of
heterozygosity in the X chromosome. Loss of heterozygosity (LOH) of the X
chromosome was found in 50% of the type III gastric carcinoids but in none of the type I
gastric carcinoid tumors. Tumors that had LOH were associated with the presence of
metastasis (116). Regarding midgut carcinoids, CGH analysis showed distinct losses in
16q and gains in chromosome 4, distinguishing primary from metastatic carcinoid issue
(117).
It is apparent that the delineation of the molecular basis of carcinoid tumor
development and evolution will provide a reliable means to characterize them, facilitate
diagnosis, rationalize therapy, and establish prognostic protocols. The tools in our
armamentarium include quantitative RT-PCR (118), automated tissue microarray analysis
(119), CpG Island Methylation analysis (120), and cDNA microarray (121) coupled with
pathway analysis, to name a few. The incorporation of these molecular techniques in
carcinoid investigation will provide the impetus for a paradigm shift, thus enhancing
current classification strategies.
The utility of cDNA microarray analysis and molecular signatures has been
demonstrated in colonic (122, 123), breast (124, 125), and bladder (126) carcinomas. The
results of these studies could potentially alter treatment protocols for cancer patients. In
2004, Y. Wang et al.(123) utilized Affymetrix™ cDNA microarray technology to find
prognostic markers for tumor relapse in patients with Dukes’ B Colon Cancer. Colonic
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carcinomas under this classification extend into or through muscular layer and have no
nodal involvement. Unfortunately, 25 to 30% of patients develop recurrence and die
(127) which created a controversy over appropriate administration of adjuvant
chemotherapy (128). Wang et al. identified a 23-gene signature that predicts recurrence
with an overall performance accuracy of 78%. This data may aid in appropriate
therapeutic decisions according to genetic profile as it revealed patients at a high risk of
relapse (13-fold) who would be appropriate candidates for adjuvant therapy similar to
Dukes C patients (123). cDNA microarray technology and gene expression profiling have
the potential to change therapeutic rationale, thus improving patient outcome.
The work of Wang et al. is demonstrative of the potential power of the
incorporation of molecular analysis in diagnostic, therapeutic, and prognostic strategies.
Within the realm of gastrointestinal carcinoids, little molecular information has been
uncovered to date (reviewed in Zikusoka et al., 2005 (129)). With the advent of high
throughput technologies such as cDNA microarrays, tissue microarrays, and quantitative
real time PCR, it may be possible to further our current understanding of the molecular
basis of GI carcinoid tumorigenesis.

4. Molecular Focus: Epigenetics and Small Intestinal Carcinoids
The goal of this thesis is to explore molecular methods of small intestinal
carcinoid (SIC) classification while elucidating potential molecular pathways involved in
their development and acquisition of malignant traits. A preliminary investigation of the
gene expression profile of SIC through Affymetrix™ GeneChip® analysis has led to a
focus on histone deacetylase 2 (HDAC2) and metastasis associated protein-1 (MTA1)
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[FIGURE 2]. These two proteins are components of epigenetic processes: HDAC2 as a
mediator of histone deacetylation and chromatin remodeling (4), and MTA1, found in
complex with HDAC2,(7) not only as a mediator of transcriptional repression (8) but of
cellular growth (9) and motility (10).
4a. Epigenetics Overview
Epigenetics is defined as the study of changes in gene function that are mitotically
and/or meiotically heritable and do not involve a change in nuclear DNA sequence (2, 3).
Methylation and histone acetylation/deacetylation are modes of epigenetic modulation.
Before a discussion of epigenetics and its potential role in tumorigenesis, a brief review
of DNA packaging is presented.
Genetic material is packaged into chromatin (130, 131). This chromatin is
composed of nucleosomes and DNA. In each nucleosome, roughly two superhelical turns
of DNA (approximately 146 base pairs) wrap around an octamer of core histone proteins
formed by four histone partners: H3-H4 tetramer and 2 H2A-H2B dimers bound by H1, a
linker histone (132). Histones are small basic proteins with a positively charged Nterminus that protrude from the nucleosome. They are involved in the determination of
the level of DNA condensation.
4a.i. Histone (De)Acetylation
The addition of acetyl groups to the N-terminal tails of the histones is a means of
influencing the level of chromatin condensation, and thus the transcriptional activity, of a
genetic region. This process is catalyzed by histone acetyltransferases (HATs) and the
hydrolysis of the acetylated histone tails is facilitated by histone deacetylases (HDACs)
(133). The acetylation of histone proteins neutralizes the positive charge, resulting in the
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disruption of higher order structures in chromatin (134), thus enhancing the access of
transcription factors and RNA polymerases to promoter regions of DNA. Deacetylation
restores the positive charge, allowing the chromatin to condense into a tightly
supercoiled, transcriptionally silent conformation, precluding the access of transcription
factors to the DNA and inevitably repressing transcription (4, 133).
4a.ii. DNA Methylation
DNA methylation, another mode of epigenetic modulation, involves the addition
of a methyl group to cytosine at the C5-pyrimidine position. This is facilitated by DNA
methyltransferases (DNMT1, 3a, and 3b) (135, 136). This post-synthetic addition alters
the appearance of the major groove of DNA, affecting the interactions with DNA binding
proteins. The sites of methylation are in the CpG Islands. These islands are found in
association with genes, usually in the promoter regions (137, 138). This modification
renders a gene transcriptionally silent as gene-specific methylation patterns correlate
inversely with gene activity (139). Methylation also mediates the formation of a
multiprotein repression complex that results in the recruitment of HDACs (140, 141),
thus promoting another mode of transcriptional repression.
Aberrations in methylation and histone deacetylation coupled with HDAC2
overexpression has been implicated in multiple cancers. Through immunohistochemistry,
Song et al.(5) observed an increase in HDAC2 expression in association with aggressive
tumor growth in human gastric cancer specimens. Aberrant recruitment of HDACs has
also been noted in acute myelogenous leukemia (142). With regard to
gastroenteronpancreatic neuroendocrine tumors, Chan et al. noted distinct methylation
patterns in the promoter regions of certain genes including p14, p16, cox2, and the
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estrogen receptor. Specifically in carcinoids, methylation of the p16 promoter region
correlated with metastatic status.
A major difference between genetic and epigenetic events is that latter may be
reversed by chemical agents (143). Current therapeutic strategies for certain malignancies
include DNA methylation inhibitors and HDAC inhibitors (144, 145). These strategies
have been used in treating leukemias (146) and lymphomas (147). Trichostatin A (TSA)
and Sodium Butyrate (SB) (HDAC inhibitors) were found to dramatically induce
apoptosis and down-regulate bcl-2 expression in B cell lymphomas with t(14;18)
translocations (148). 5-azacitidine, a DNA methylation inhibitor, has been used in the
treatment of acute myelogenous leukemia (149) and of refractory anemia in patients with
myelodysplastic disorders (150) with promising results. HDAC and DNA methylation
inhibitors may also be of utility in solid organ tumors (151, 152).

5. A Focus on the MTA1 Complex: Histone Deacetylase 2 and Metastasis
Associated Protein 1
5a. Histone Deacetylase 2 (HDAC2)
Histone Deacetylase 2 (HDAC2) is a major component of normal and aberrant
epigenetic processes. Increased expression has been noted in gastric (5) and colorectal (6)
carcinomas. Most notably, the overexpression of this enzyme has been associated with
aggressive disease course in gastric cancer patients (5).
Located on 6q21 (153), the gene for HDAC2 encodes a 488 amino acid protein
that localizes to the nucleus. There are 4 major groups of histone deacetlyases. Class I
includes HDAC1, HDAC2, HDAC3, and HDAC8. Class II includes HDAC4, HDAC5,
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HDAC6, and HDAC7 (154). The Sir2 (155) and maize HD2 (156) families complete the
list.
5a.i. Function:
HDAC2 is an enzyme capable of removing an acetyl-group from the N-terminal
lysines of histone proteins. This acetylation leads to the deneutralization of the positive
histone charge and results in a change in DNA conformation. This process serves as a
means of transcriptional repression. An increase in local concentrations of HDAC2 has
been noted in association with hypoacetylated chromatin (157).
Histone deacetylation can be triggered by DNA methylation when HDAC2 is a
part of the Nucleosome Remodeling and Deacetylating (NuRD) complex, which contains
MTA2, HDAC1/2, RbAp48/p46 (histone binding proteins), and MBD3 (methyl-CpGbinding domain-containing protein 3- mediates the association of MTA2 with the core).
This NuRD complex interacts with Methylation Binding Domain 2 (MBD2) and directs
the complex to methylated DNA. This provides a means expression regulation of
methylated DNA via histone alternation (158).
HDAC2 is also found in complex with MTA1, the second protein of focus in our
investigation. This relationship will be further discussed in the next section.
5a.ii. Regulation:
In colorectal cancer models, HDAC2 expression is regulated by the APC
(Adenomatosis Polyposis Coli)/Beta-Catenin pathway. The loss of the APC gene resulted
in increased HDAC2 expression. Through chromatin immunoprecipitation, c-Myc was
found bound to the HDAC2 promoter region. This is proposed to directly upregulate
HDAC2 expression (6).
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5b. Metastasis Associated Protein 1 (MTA1)
Metastasis associated protein 1 (MTA1) may have a pivotal role in the aggressive
nature and the metastatic status of many different tumors. Over-expression of MTA1
mRNA and protein correlates with tumor invasion and metastasis in various tumors
including breast (11, 159), hepatocellular (12), esophageal (13), gastric and colorectal
carcinomas (14). With regards to breast cancer, MTA1 overexpression is linked to a high
risk of recurrence. These cases, however, have favorable responses to systemic therapies
(160).
Located on 14q32.3 (161), the MTA1 gene encodes a 702 amino acid protein that
is localized to the nucleus. In 2002, Kumar et al. identified a shorter splice variant of
MTA1, MTA1s (430 amino acids). Localized to the cytoplasm, this protein is involved in
the sequestration of Estrogen Receptor-alpha (ERα) in the cytoplasm. MTA1s expression
is increased in human breast tumors with no or low nuclear ER (162).
5b.i. Function:
MTA1 has been implicated in transcriptional repression, chromatin remodeling,
cellular growth, and cell motility.
5b.i.a. Transcriptional Repression:
MTA1 represses transcription of genes under the control of estrogen-responsive
elements (EREs). It functions via direct binding to ERα (8), direct binding to ERα
coactivators (163, 164), or via the recruitment of HDAC2 (7).
Mazumdar et al. found that, by binding to the activation domain of ERα, MTA1
acts as a potent corepressor of the transcription of ERE-associated genes. Mazumdar et
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al. concluded that ERα-mediated transcription was a target of MTA1 as it acted as a
corepressor (8). In 2004, Moon et al. reported that in hepatocellular carcinoma, MTA1
expression correlated inversely with the presence of nuclear ERα. The presence of this
protein was also associated with increased tumor size and increased angioinvasion (12).
With regards to indirect repression of ERE-controlled genes, MTA1 may work
through the nuclear receptor co-activator designated as NRIF3. Normally, this protein
acts as an ER coactivator, resulting in the hyperstimulation of ER transactivation. The
binding of MTA1 to NRIF3 results in transcriptional repression of genes under the
control of EREs (163). Similar repressive activity was previously found with MiCoA
(MTA1-interacting coactivator), a protein with similar ER-coactivator functions (Mishra
et al., 2003) (164).
5b.i.b. Chromatin Remodeling:
MTA1 has been found in complex with HDAC1/HDAC2, Mi-2beta, and
RbAp48/p46, forming the Nucleosome Remodeling and Deacetylating (NURD) complex
(7). Mi-2beta is a dermatomyositis-associated autoantigen (165) that may have helicase
properties (166). RbAp48/p46 are histone binding proteins (167). (This complex is unlike
the previously mentioned NuRD complex involving MTA2.)
An investigation by Toh et al. (13) demonstrated MTA1’s association with
histone deacetylase activity. Through immunhistochemistry, the group found an inverse
relationship between MTA1 and the acetylation status of H4 in cases of esophageal
squamous cell carcinoma (13). Mazumdar demonstrated the repression of MTA1mediated transcription through the use of Trichostatin A, a histone-deacetylase inhibitor
(8).
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5b.i.c. Cellular Growth:
MTA1 may induce abnormal tissue growth. In a study of transgenic mice,
Bagheri-Yarmand et al. (9) (2004) showed that MTA1 was involved in increased
proliferation of ductal and alveolar epithelial cells. The administration of antisense
oligonucleotides specific for MTA1 prohibited the rapid growth of human breast cancer
cells with high MTA1 expression (168). This protein may be a mediator of aggressive
breast cancer development and progession.
5b.i.d. Cell Motility:
Multiple investigations have demonstrated MTA1’s effect on cell motility,
potentially mediating the movement and invasion of metastatic cells. Utilizing the
PANC-1 pancreatic carcinoma cell line, Hofer et al. (10) found that, by inducing MTA1
overexpression through the transfection of an EGFP-MTA1 fusion protein, cellular
motility was markedly enhanced. There was also a concomitant increase in the invasive
penetration of epithelial barriers by the cells with actual modulation of the cytokeratin
filament system. These findings suggest an indirect role for MTA1 in the enhancement of
cell motility, thus potentiating the metastasis of tumor cells (10). MTA1 also enhanced
the migration and invasion of immortalized human keratinocytes. Mahoney et al. (2002)
purported that MTA1 expression may depend, in part, on the activation of the Epidermal
Growth Factor Receptor (EGFR). Similar to the investigations of Mazumdar et al. (2001),
this group suggested MTA1 enhancement of anchorage-independent cell survival (169).
5b.ii. Regulation:
In 2001, Mazumdar et al. suggested that the transcription of this gene may be
under the control of the heregulin/HER2 pathway. This pathway has been implicated in
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the suppression of ERE-driven transcription- thus decreasing the estrogen-responsiveness
of a cell. Through in vitro studies using ERα positive breast cancer cells, Mazumdar
found that stimulation with heregulin (HRG) led to increased expression of MTA1.
Stimulation of cells with HRG also led to the suppression of histone acetylation and
increased deacetylase activity (8).
In the fall of 2005, Zhang et al. (170) published a key regulatory finding. c-MYC,
an oncoprotein that is highly expressed in many cancers (171-173), may be the upstream
regulatory element involved in the regulation of MTA1 expression. Through cell lines
transformed with a c-MYC/ER fusion protein and a mouse animal model, this group
found a direct correlation between c-MYC and MTA1 expression. This may occur
through the direct recruitment of histone acetyltransferases (HAT) to the MTA1 promoter
region mediated by MbII, an element in the N-terminal transactivation domain of c-MYC
(174, 175) that facilitates the assembly of HAT complexes. These complexes acetylate
the lysine of histones, thus neutralizing the positive charge and changing the chromatin
conformation.
Overall, it appears that MTA1 expression may be under the control of the
HRG/HER2 pathway and it may also be mediated by c-MYC, an oncoprotein highly
expressed in multiple carcinomas. Further analysis of MTA1’s promoter region may lead
to the discovery of other transcriptional control elements.
5c. HER2, ERα, and GI Carcinoids:
One of the paradigms of successful endocrine-targeted therapy in tumor disease is
breast cancer (176). The exploration of endocrine pathways in breast cancer has led to the
discovery of successful endocrine-targeted therapies such as Tamoxifen (177) and
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Herceptin (178). These therapies, operating via the ERα and HER2 (neu or erb-B2)
pathways, respectively, have proven successful in the inhibition of cell proliferation. The
logic behind these therapies is based upon a correlation between receptor presence and
clinical profiles. HER2, a member of the epidermal growth factor receptor family, is
genetically amplified and over-expressed in aggressive breast cancers and high levels are
associated with poor prognosis, particularly in node-positive breast carcinoma patients
(179) In contrast, the presence of ERs typically indicates slower-growing tumors that
may be amenable to hormonal manipulation (180).
The description of the existence of ERα on carcinoid tumors (181) eventually led
to the exploration of Tamoxifen therapy in these tumors. One group reported repression
of carcinoid syndrome symptoms with tamoxifen therapy. The therapeutic benefits,
however, diminished one year later as the symptoms returned (182). Later reports
presented similar negative results (183, 184). Despite these data, estrogen and its receptor
may have a role in carcinoid tumors. Recent studies by Chan et al. (185) reported
promoter methylation of the ERα gene in 63% (10 of 16) GI carcinoid tumors. Overall,
evidence for the presence of the ERα in gastrointestinal (GI) carcinoid tumors, however,
remains equivocal while the biological role of estrogen in gastrointestinal carcinoid
tumor proliferation is controversial. Conversely, HER2/neu amplification has been
identified in 4 out of 10 carcinoid tumors of the gut; three of which were invasive or
metastatic (186). Although the presence of HER2/neu has been suggested, the role of
these receptors and their respective pathways remains to be explored in GI carcinoids.
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6. A Statement of Purpose
The aims of the current study were to examine the biological and clinical
significance of the MTA1/HDAC2 complex in Small Intestinal Carcinoids. Techniques
utilized in this investigation include cDNA Microarray, Pathway Analysis, Q-RT-PCR,
Tissue Microarray, and Enzymatic Assays.
An interrogation of HDAC2 and MTA1 genetic and protein expression, coupled
with functionality, will enable the delineation of an association between epigenetic
modulation and SIC development and progression. This analysis may also aid in the
classification of malignant carcinoids. In addition, the presence of such a relationship
may indicate the potential therapeutic utility of HDAC inhibitors in the treatment of SIC.
The examination of ERα and HER2/neu could identify subtypes of SICs that may
respond to endocrine-targeted therapies, while the exploration of the relationship between
the ERα and HER2 pathways with MTA1 may provide insight into the tumorigenesis and
acquisition of malignant traits in SICs. To delineate the relevance of these pathways in
SIC, alterations in gene and protein expression of ERα, Trefoil Factor 1 (TTF1/pS2- a
downstream gene under the control of estrogen (187, 188)) and HER2/neu in SICs were
measured. Since ERα, HER2, and MTA1 expression have been previously wellcharacterized in breast tissue, both normal and cancerous breast specimens were used as
controls.
In addition to HER2 pathway analysis in the upregulation of MTA1 gene
expression, we analyzed the promoter region of this gene, to identify other potential
mediators of transcriptional activation. This was undertaken using a computer to search
for the presence both of transcription factor element sites and CpG methylation islands.
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To investigate the promoter region, primers were developed to isolate the region for
future methylation profile studies.

7. Hypothesis
We hypothesize:
1) Aberrant transcriptional regulation is central to SIC tumorigenesis and the
development of metastasis.
2) MTA1 and HDAC2 proteins, in epigenetic processes, have functional roles in
SIC development and may aid in the classification of SIC subtypes, thus
facilitating improved diagnosis and prognostication.
3) There will be an inverse relationship between MTA1 expression and ERαcontrolled gene products such as TFF1.
4) The Heregulin/HER2 pathway is involved in the upregulation of SIC MTA1
expression.
5) CpG island (de)methylation may be a cause of MTA1 overexpression in SICs.
To summarize, we hypothesize that aberrant epigenetic functions, mediated by the
MTA1/HDAC2 complex, are important for SIC development and malignant progression.

8. METHODS
8a. Tissue Specimens
8a.i. Construction and Processing of Small Intestinal Carcinoid TMA. Formalinfixed paraffin-embedded tissue blocks containing 101 GI carcinoids (stomach: n=5;
duodenum: n=4; small bowel and ileocecal: n=55; appendix: n=25; colon: n=12) were
retrieved, along with the corresponding H&E-stained slides, from the archives of the
Yale University School of Medicine Department of Pathology. Blocks were stored
under ambient conditions within a temperature range of 18-37°C. To ensure uniformity
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of sectioning, older paraffin blocks were melted and re-embedded using modern-day
plastic cassettes. Areas of carcinoid, areas of normal tissue, lymph node metastases and
liver metastases were identified by Dr. R.L. Camp and marked for subsequent retrieval
and analysis. Core biopsies 0.6 mm in diameter were taken from each donor block and
arrayed into a recipient paraffin block (45 mm x 20 mm) using a tissue puncher/arrayer
(Beecher Instruments, Silver Spring, MD) as described by Xie et al.(189) The array
contained 101 cases of primary GI carcinoids (55 of which were small intestinal) and
matched normal tissue, 15 lymph nodes and 7 liver metastases diagnosed between 1965
and 2003. The array was created by Lori Charette of the Yale Cancer Center Tissue
Microarray Facility. For the SIC patients, follow-up information was available (median
follow-up: 103 months, range: 29-264 months) for all small intestinal carcinoid patients
[Table 1].

Table 1. Characteristics of carcinoid patients (n = 55) on the tissue microarray
Anatomical Site

Male:Female
ratio

Age
Liver
Lymph node Follow-up
Median
involvement involvement* (months)
Median (range)
(range)
Small bowel (n = 55) 19:21
62 (40-89) 8/38
21/38
103 (29-264)
ANED = Alive no evidence of disease; AWD = Alive with disease. *p=0.00043, **p<0.00001

Survival
Status**
ANED:AWD
5:33

8a.ii. Fresh Tissue. Tumor tissue from seven patients (M:F = 6:1; median age [range] =
58 yr [40-73]) diagnosed with GI malignancies were collected for this study [Table 2].
Seven small bowel EC carcinoids (n=7) were examined; four patients had matched
normal mucosa (n=4). Tissue was collected from the Department of Surgical Pathology
(Yale University School of Medicine) and from the Cooperative Human Tissue Network
which is funded by the National Cancer Institute. None of the patients had received
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therapy (surgery or somatostatin analogs) prior to tissue procurement. Paired normal
tissue samples were also obtained from adjacent, macroscopically normal, non-tumor
mucosa in seven patients. In addition tumor (n= 5) and normal (n=5) breast tissue were
used as controls (Courtesy of Dr. D. Lannin and the Yale University Department of
Pathology). None of the breast patients had received therapy (radiation or
chemotherapeutics) prior to tissue procurement. Fresh tissue was acquired by M.
Zikusoka.

Table 2. Carcinoid tumor patients and specimens
Sex Age# Site of primary tumor Tissue analyzed
Liver metastasis LN metastasis
F
40
Small Bowel
Liver metastasis/liver Y
N
M
73
Small Bowel
EC carcinoid/Normal Y
Y
M
48
Small Bowel
EC carcinoid/Normal M
64
Small Bowel
EC carcinoid
Y
Y
M
58
Small Bowel
EC carcinoid
Y
Y
M
73
Small Bowel
EC carcinoid/Normal N
Y
M
55
Small Bowel
EC carcinoid
Y
*
normal tissue available, # age at time of procedure, LN = lymph node, - = no data available

No.
*
1.
*
2.
*
3.
4.
5.
*
6.
7.

8b. Molecular Biological Techniques
8b.i. cDNA Microarray Construction. Material from 12 small intestinal tissue blocks
(n=11 patients; normal small intestinal mucosa: n=4, malignant small intestinal
carcinoids [that had clinical evidence of liver and lymph node metastases]: n=8) was
examined using Affymetrix™ GeneChip® (Santa Clara, CA) analysis. Tissue was microdissected and histologically verified (by Dr. R.L. Camp) to be free of non-tumor cells.
Total RNA was isolated from each sample using the Rneasy® kit (Qiagen). Target
cDNAs were generated and hybridized to human HU133A GeneChip® (Affymetrix,
Santa Clara, CA). The intensity was equally scaled for each chip (intensity = 500) and
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genes normalized using the RMA algorithm. Thereafter, differences in gene expression
between tumors and normal mucosa were examined using GeneSpring® software
(Agilent Technologies, Palo Alto, CA). Analysis was performed by Dr. M. Kidd and Dr.
S. Mane.
8b.ii. Pathway Analysis. Ingenuity® Pathway Analysis (Redwood City, CA) was used
to identify gene networks of interest. This approach allows identification and biological
exploration of gene networks of potential therapeutic relevance that are significantly
expressed in gene expression data. These pathways are scored, with scores >2 having at
least a 99% chance of not being generated by random chance alone (Ingenuity ® Pathway
Analysis manual). Analysis performed by Dr. M. Kidd.
8b.iii. RNA Isolation. Total RNA was isolated from fresh frozen small intestinal
carcinoid tumor tissue (n=7), fresh frozen breast tumor tissue (n=5), normal SI mucosa
(n=4), and normal breast tissue (n=5) using TRIzol reagent (Invitrogen, Carlsbad, CA)
using the manufacturer’s guidelines. RNA was dissolved in DEPC water, measured
spectrophotometrically and an aliquot analyzed on a denaturing gel using electrophoresis
to check the quality of RNA isolated. (M. Kidd and M. Zikusoka)
8b.iv. Q RT-PCR. ERα, TFF1, HER2/neu, HDAC2, and MTA1 message was
quantitatively measured in the 11 samples. PCR was performed using the ABI 7900
Sequence Detection System. Total RNA from each sample was subjected to reverse
transcription using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster
City, CA) following the manufacturers suggestions. Briefly, 2μg of total RNA in 50 μl of
water was mixed with 50 μl of 2X RT mix containing Reverse Transcription Buffer,
dNTPs, random primers and Multiscribe Reverse Transcriptase. RT reaction was carried
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out in a thermal cycler for 10 min at 25°C followed by 120 min at 37°C. Real time PCR
analysis was then performed. cDNA in 7.2 μl of water was mixed with 0.8 μl of 20 x
Assays on Demand® primer (Applied Biosystems, Foster City, CA) (ERα =
Hs00174860, TFF1 = Hs00170216, HER2/neu = Hs00170433, HDAC2 = Hs00231032,
MTA1 = Hs00183042, GAPDH = Hs99999905) and probe mix, 8 μl of 2x TAQMAN
Universal Master mix in a 384 well optical reaction plate. The following PCR conditions
were used: 50°C for 2 min, then 95°C for 10 min, followed by 40 cycles at 95°C/0.15
min and 60°C /1 min. A standard curve was generated for each gene using cDNA
obtained by pooling equal amounts from each sample (n=11). The expression level of
target genes was normalized to internal GAPDH. Data was analyzed using Microsoft ®
Excel (2002) and calculated using the relative standard curve method (ABI, User Bulletin
#2). (M. Kidd and M. Zikusoka)
8b.v. Tissue microarray immunostaining, image acquisition and data analysis. For
antigen retrieval purposes, tissue microarray slides were immersed in citrate buffer (10
mm sodium citrate, pH 6.0), and subjected to 1 x 10 min high temperature-high pressure
treatment followed by the treatment with 0.3% H2O2 in methanol for 30 min at 37°C to
inactivate endogenous peroxidase. Slides were incubated for 24 hr at 4°C with primary
antibodies diluted in Tris-buffered saline containing BSA. Primary antibodies used
included mouse monoclonal anti-ERα (1:500; DAKO Corp., Carpinteria, CA), mouse
monoclonal anti-HER2/neu (1:500 and 1:5,000; DAKO Corp., Carpinteria, CA), mouse
monoclonal anti-TFF1 (pS2, 1:500, NovaCastra. New Castle, England), mouse
monoclonal anti-HDAC2 (1:200, Santa Cruz Biotech, Santa Cruz, CA), and mouse
monoclonal anti-MTA1 (1:100, Santa Cruz Biotech, Santa Cruz, CA). Goat anti-mouse
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antibody conjugated to a horseradish peroxidase-decorated dextran polymer backbone
(Envision; DAKO Corp, Carpinteria, CA) was used as a secondary reagent. For
automated analysis, tumor cells were identified by the use of a fluorescently tagged
anticytokeratin antibody cocktail (AE1/AE3; DAKO Corp, Carpinteria, CA), nuclei were
visualized by 4’,6-diamidino-2-phenylindole (DAPI), and targets visualized with a
fluorescent chromogen (Cy-5-tyramide; NEN Life Science Products, Boston, MA).
Antibody expression on the carcinoid tissue microarray was determined using an
automated tissue microarray reader controlled by 2 observers (M. Kidd (M. Zikusoka) and
R.L. Camp). Automated image acquisition and analysis using AQUA was developed by
Dr. R.L. Camp (190). In brief, monochromatic, high-resolution (1024 x 1024 pixel; 0.5mm) images were obtained of each histospot. Areas of tumor from stromal elements were
distinguished by creating a mask from the cytokeratin signal. Coalescence of cytokeratin
at the cell surface localized the cell membranes, and DAPI was used to identify nuclei.
The target signal from the membrane area of tumor cells was scored on a scale of 0–255
and expressed as signal intensity divided by the membrane area. Histospots containing
<10% tumor, as assessed by mask area (automated), were excluded from further analysis.
Previous studies have demonstrated that the staining from a single histospot provides a
sufficiently representative sample for analysis (191). Disc scores from the same tumor
were averaged to produce a single score. (M. Kidd and M. Zikusoka)
8b.vi. Indirect HDAC2 Activity Assessment. HDAC2 activity was indirectly evaluated
using immunohistochemical techniques. Amounts of acetylated Histone 2B and
deacetylated Histone 2B were analyzed in contrast to HDAC2 expression. For antigen
retrieval purposes, tissue microarray slides were immersed in citrate buffer (10 mm
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sodium citrate, pH 6.0), and subjected to 1 x 10 min high temperature-high pressure
treatment followed by the treatment with 0.3% H2O2 in methanol for 30 min at 37°C to
inactivate endogenous peroxidase. Slides were incubated for 24 hr at 4°C with primary
antibodies diluted in Tris-buffered saline containing BSA. Primary antibodies used
included mouse monoclonal anti-H2B (1:200, Santa Cruz Biotech, Santa Cruz, CA) and
mouse monoclonal anti-acetylated H2B (1:500, Santa Cruz Biotech, Santa Cruz, CA).
Goat anti-mouse antibody conjugated to a horseradish peroxidase-decorated dextran
polymer backbone (Envision; DAKO Corp, Carpinteria, CA) was used as a secondary
reagent. For automated analysis, tumor cells were identified by the use of a fluorescently
tagged anticytokeratin antibody cocktail (AE1/AE3; DAKO Corp, Carpinteria, CA),
nuclei were visualized by 4’,6-diamidino-2-phenylindole (DAPI), and targets visualized
with a fluorescent chromogen (Cy-5-tyramide; NEN Life Science Products, Boston,
MA). Antibody expression on the carcinoid tissue microarray was determined using an
automated tissue microarray reader controlled by 2 observers (M. Kidd (M. Zikusoka)
and R.L. Camp). Automated image acquisition and analysis using AQUA was developed
by Dr. R.L. Camp(190). Disc scores from the same tumor were averaged to produce a
single score. Data was then compared with regards to acetylation status and HDAC2
staining patterns. (M. Kidd, R.L. Camp, M. Zikusoka, and G. Eick)
8b.vii. HDAC Activity Assay. HDAC proteins were isolated from SIC tumor samples
and normal SI mucosa. Samples were ground to a fine powder using mortar and pestel
under liquid nitrogen and immediately resuspended in RIPA lysis buffer including
0.1mM phenylmethylsulfonyl fluoride and freshly added protease inhibitor cocktail
(Roche, Indianapolis, IN). After homogenization by syringe shearing, samples were
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centrifuged at 10,000g for 15 min at 4°C. The resulting supernatant was used for the
HDAC assay. Enzyme activity in normal and tumor samples was measured using the
HDAC Colorimetric Activity Assay kit (Biomol) following the protocol provided by the
supplier. The assay is based on cleavage by HDAC1/2 of an acetylated lysine side chain
in the Colorimetric Histone Deacetylase Lysyl Substrate. The optimal conditions were
first established (60 minute incubation period; substrate concentration = 0.6mM, protein
concentration = 25mg total protein/experiment) and reaction kinetics of HDAC activity
was determined in pooled total protein samples (n=4) from isolated from SIC tumor and
normal bowel samples. The Km of the enzymatic activity was ~0.45mM; the apparent Km
of HDAC is 0.42mM for HeLa nuclear extracts (Biomol kit insert). This demonstrates
that HDAC activity can be measured in proteins extracted from fresh-frozen surgical
samples. The specificity of HDAC activity was demonstrated by inhibition with 1µM
Trichostatin A – a HDAC Class I and II inhibitor. In these experiments, HDAC activity
was measured in triplicate in each sample. Samples included normal mucosa (n=3) and
small intestinal carcinoid (n=4). Comparisons were made using 2-way ANOVA
(p<0.05). (M. Kidd, M. Zikusoka and G. Eick)
8b.viii. MTA1 Promoter Region Analysis. The promoter sequence for the MTA1 gene
was examined using Chromas® version 2.31 (Technelysium Ltd). The promoter region
was analyzed for the presence of response elements which may be responsible for the
control of transcription of the MTA1 gene. The search included TATA boxes (TATA),
SP1 promoter sites (GGGCGG), c-Myc (CACGTG), c-Fos/c-Jun (TGACTCA &
TGAGTAA), GATA (AGATA/TGATA), Retinoic Acid Receptor (GTTCAC), CREB
(TGACG), and E2F (TTTCGCGGCAAA) and CpG methylation islands. TESS:
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Transcriptional Element Search System (www.cbil.upenn.edu/tess) was utilized to find
the nucleotide patterns of the aforementioned transcription elements. (M. Kidd and M.
Zikusoka).
8b.ix. Isolation of MTA1 Promoter Region. After the analysis of the promoter region of
the MTA1 gene, the following primers were designed by visual analysis in order to isolate
the promoter region: MNZF1: CCG CTC CAT GTC CTA CAG AG, MNZR: CTG GTA
GAT CCT CCC CTG GT, MNZF2: GAG GAT CTA CCA GGG GGT TC, MNZR2A:
CTC CTG CTC CCA GAC CGG CA, MNZR2B: CAA AAC TCC TGC TCC CAG AC
and MNZR2C: CTC CGA CCC TGT ACA TGT TGG CG. All primers were constructed
at the W.M. Keck Oligonucleotide Synthesis Facility at Yale University. PCR was used
to amplify the MTA1 promoter region. Total DNA from samples (normal liver, gastric
carcinoid, SIC with liver metastasis, gastrinoma with lymph node metastasis) was
extracted using standard phenol/chloroform methods after samples were ground to a fine
powder using mortar and pestel under liquid nitrogen. Each reaction tube contained 2μL
genomic DNA in 18.9μL H2O, 2.5μL 10X buffer, 1.5mM MgCl2, 0.5μL dNTPs, 0.5μL
forward primer, 0.5μL reverse primer, and 0.1μL Taq polymerase. PCR Core Kit (Roche
Applied Science, Indianapolis, IN). Using primer combinations of MNZF1/R1,
MNZF1/R2C, MNZF2/R2A, MNZF2/R2B, MNZF2/R2C, PCR was carried out in a
thermal cycler for 35 cycles (Denaturing Temperature: 95 degrees, 30 seconds;
Annealing Temp: 55degrees, 45 seconds; Extension Temperature: 72 degrees, 1 minute).
Expected product lengths were 848, 1259, 800, 805, and 424 bases, respectively.
MNZF1/R2A and MNZF1/R2B primer combinations were not pursued due to the
excessive length of expected products (1635 and 1640 bases, respectively). Gel
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electrophoresis was used to confirm product presence and length. Sequences of the PCR
products were produced by W. M. Keck DNA Sequencing Facility at Yale University.
The Basic Local Alignment Search Tool (Blast-N)® program provided by the National
Center for Biotechnology Information (NCBI) (www.ncbi.nlm.nih.gov) was used to was
used verify product identities. (M. Zikusoka and G. Eick)
8b.x. Statistical analysis. Results of Q RT PCR and AQUA were expressed as mean ±
SEM; n indicates the numbers of patients in each study group. Statistical significance was
calculated by the two-tailed Student’s test for paired and unpaired values as appropriate,
with a probability of < 0.05 representing significance.

9. RESULTS
9a. Gene Expression Profile Analysis:
Affymetrix GeneChip analysis of SIC identified 1709 genes significantly altered in
malignant SIC tumors compared to normal small intestinal mucosa. Hierarchical
clustering of 12 Affymetrix chips which included normal small intestinal mucosa (n=4)
and malignant SIC tumors (n=8) was performed at the W.M. Keck Affymetrix Facility at
Yale University, revealing a clear genetic distinction between gene expression profiles of
normal mucosal and tumor tissue. Ingenuity Pathway Analysis allowed the delineation of
gene networks with significant differences in gene expression between normal and tumor
tissue prominent aberrations in the gene profile analysis. The highest scoring pathway
was the HDAC-related transcriptional repression pathway [FIGURE 2]. These results led
to a focus on HDAC2 and MTA1, two genes involved in epigenetics and transcriptional
repression.

42

Fig 2. Hierarchical clustering of 12 Affymetrix chips including
normal small intestinal mucosa (N; n=4) and malignant small
intestinal carcinoid tumors (T; n=8). There is a clear separation
between normal mucosal genes and tumor genes. Expression levels
–3.0→+3.0 are indicated below.

9b. Message Expression Analysis through Q RT-PCR:
Real-time PCR analysis was undertaken using Assays on Demand (Applied Biosystems)
products on cDNA from seven small bowel carcinoids and four macroscopically normal
adjacent mucosal samples to quantitatively measure the levels of ERα, TFF1, HER2/neu,
HDAC2, and MTA1 mRNA expression. We used primary breast tumor tissue as controls
and obtained the following message profiles: ERα- 2.518±1.05, MTA1- 0.5±0.26, TFF10.19±0.09, HER2- 0.5±0.18. Levels of all these factors were increased compared to the
normal breast specimens: ERα- 0.088±0.035, MTA1- 0.38±0.21, TFF1- 0.00, HER20.12±0.06.
9c. Tissue Microarray:
The clinical characteristics of the fifty-five SIC patients are given in Table 1 (See page
24). A comparison of normal small intestinal mucosa and the primary tumors of patients
with and without disseminated disease (i.e. presence of lymph node or liver metastases) is
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indicated below. No statistically significant differences in these characteristics were
noted except in the distribution of lymph node involvement (χ2=20.4, p<0.0005) and
survival status (χ2=32.1, p<0.00001).

Fig. 3. MTA1 expression. Triple staining of small
intestinal carcinoid histospot on tissue microarray.
Green = cytokeratin (FITC). Blue = nuclear-staining
(DAPI). Red = MTA1 staining (Cy5). Purple =
colocalization of MTA1 in the nucleus.

9d. MTA1 in Small Intestinal Carcinoids
9d.i. Q-RT-PCR Analysis:
We observed elevated message levels of MTA1 in the primary and metastatic SIC tumor
samples compared to normal tissue (3.58±1.5 and 5.96±2.4 vs. 1.68±0.16; p=0.05 and
p<0.05). [FIGURE 4A]
9d.ii. Tissue Microarray Analysis:
An examination of the MTA1 stained histospots from the 55 SIC patients on the TMA
demonstrated MTA1 expression. Differences in MTA1 expression in local (75±12) and
disseminated (78±1) SIC specimens compared to normal (3±1) were of statistical
significance (p=0.05, p<0.01). A comparison of the AQUA scores of SIC specimens in
patients with local vs. disseminated disease (Mean AQUA Score: 75±12 vs. 78±1) is not
of statistical significance. [FIGURE 4B]
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Fig. 4. Graphical presentation of Q-RT-PCR and AQUA Analysis for MTA1 in Small Intestinal
Carcinoids. (A) Mean mRNA expression levels increased as the small intestinal specimen progressed
from normal (1.68±0.16) to primary (3.58±1.5) to metastatic (5.96±2.4) status. The changes were of
statistical significance (*p=0.05, #p<0.05). (B) Mean protein expression levels increased significantly
in the primary tumors of patients with both local (75±12) and disseminated disease (78±14) compared
to normal (3±1). These changes were also of statistical significance (#p<0.05, #p<0.05).

9e. HDAC2 in Small Intestinal Carcinoids
9e.i. Q-RT-PCR Analysis:
We observed elevated message levels for HDAC2 in the primary and metastatic SIC
tumor samples compared to normal tissue (2.0±0.8 and 4.1±0.6 vs. 0.07±0.02; p<0.003
and p<0.003). [FIGURE 5A]
9e.ii. Tissue Microarray Analysis:
An examination of the HDAC2 stained histospots from the 55 SIC patients on the TMA
demonstrated HDAC2 expression. Differences in HDAC2 expression in local (712±101)
vs. disseminated (762±105) SIC specimens compared to normal mucosa (524± 81) are of
statistical significance (p<0.05). A comparison of the AQUA scores of SIC specimens in
patients with local vs. disseminated disease (712±101 vs. 762±105) was not of statistical
significance. [FIGURE 5B]
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Fig. 5. Graphical presentation of Q-RT-PCR and AQUA Analysis for HDAC2 in Small Intestinal
Carcinoids. (A) Mean mRNA expression levels increased as the small intestinal specimen progressed
from normal (0.07±0.02) to primary (2.0±0.8) to metastatic (4.1±0.6) status. The changes were of
statistical significance (&p<0.003, &p<0.003). (B) Mean protein expression levels increased
significantly in the primary tumors of patients with both local (712±101) and disseminated disease
(762±105) compared to normal (524±81). These changes were also of statistical significance (#p<0.05,
#p<0.05).

9e.iii. HDAC2 activity in SIC cells:
The HDAC activity assay utilized protein samples from both tumor samples and normal
intestinal mucosa. The assay [Figure 6] demonstrated a significant elevation in HDAC
activity in SIC samples (4-fold; p<0.03) compared to normal mucosa. The specificity of
HDAC activity was demonstrated by inhibition with 1µM Trichostatin A (TSA). This
resulted in a 70-80% inhibition of HDAC activity in normal mucosa and SICs. Normal0.08, Normal with TSA- 0.04, SIC- 0.32, SIC with TSA- 0.081. A comparison of normal
vs. SIC HDAC activity had a p-value of <0.03. Of note, the HDAC colorimetric assay is
not specific for HDAC2 since it also measures the activity of HDAC1 and SIRT1.
Overall, the results demonstrate elevated HDAC activity in SICs, thus suggesting a role
for histone deacetylation in carcinoid tumor progression. [FIGURE 6]
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Fig. 6. HDAC Activity Assay. HDAC enzyme
activity was measured via colorimetric assay.
Activity is reflected as the amount of
absorbance measured at 405 nm. Normal vs.
SIC activity, p<0.03. NML=normal, SIC=
small intestinal carcinoid, TSA= Trichostatin
A.

9e.iv. Indirect Assessment of Histone Deacetylase 2 activity:
HDAC2 activity was indirectly assessed through the measurement of HDAC2, acetylated
H2B, and non-acetylated H2B using immunohistochemical techniques coupled with
automated analysis (AQUA). Both H2B and acetylated H2B were localized in the
nucleus. This investigation established a direct correlation with increased HDAC2
presence with decreased acetylated H2B. The acetylated form of H2B was significantly
decreased (p<0.05) in the SICs (Mean AQUA Score = 502±121) and their metastases
(523±112) compared to normal mucosa (757±116) [Figure 7]. These data not only
corroborate the HDAC2 activity assay results, but they suggest nuclear H2B
deacetylation in both tumors and their metastases.
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Fig. 7. AQUA Analysis for Acetylated
Histone 2B (H2B) in Small Intestinal
Carcinoids. Mean protein expression levels
were decreased in local (502±121) and
disseminated (523±112) SIC samples compared
to normal SI mucosa (757±116). *p<0.05.

An examination of the acetylated H2B:non-acetylated H2B ratio in SICs compared to
normal mucosa (1.43 vs. 1.74) [Figure 8] underscores the decreased acetylation level in
tumor samples.

Fig. 8. Ratios of nuclear histone 2B and
acetylated histone 2B in normal vs.
primary/disseminated SICs (1.74 vs.
1.43). These data demonstrate that
disease progression is associated with
decreased acetylation of H2B.

9f. HER2 in Small Intestinal Carcinoids
9f.i. Q-RT-PCR Analysis:
HER2 message levels were lower in both primary and metastatic SIC samples compared
to normal tissue (1.02±0.23 and 0.8±0.39 vs. 2.28±0.51; p=0.05 and p<0.05). [FIGURE
9A]
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9f.ii. Tissue Microarray Analysis:
No staining was noted for HER2/neu when the standard 1:5,000 dilution used routinely in
identifying amplified HER2/neu in breast cancers was used. However, a dilution of 1:200
detected HER2/neu positive cells on the TMA. This concentration identifies normal (nonamplified) expression of HER2/neu in breast cancers and was used to evaluate expression
levels in carcinoids. An examination of the HER2 stained histospots from the 55 SIC
patients on the TMA demonstrated HER2 expression. Differences in local (9±1) and
disseminated (6±0.5) SIC specimens as compared to normal (10±1) were not statistically
significant. A comparison of the AQUA scores of SIC specimens in patients with local
vs. disseminated disease (Mean AQUA Score: 9±1 vs. 6±0.5) was also statistically
insignificant. [FIGURE 9B]

Fig. 9. Graphical presentation of Q-RT-PCR and AQUA Analysis for HER2 in Small Intestinal
Carcinoids. (A) Mean mRNA expression levels decreased as the small intestinal specimens progressed
from normal (2.25±0.51) to primary (1.02±0.23) to metastatic (0.8±0.39) status. The changes were of
statistical significance (*p=0.05, #p<0.05). (B) Mean protein expression levels, however, did not vary
significantly when comparing the primary tumors of patients with both local (9±1) and disseminated
(6±0.5) disease to normal small intestinal mucosa (10±1). NS= not significant.
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9g. ERα in Small Intestinal Carcinoids
9g.i. Q-RT-PCR Analysis:
Message for ERα was elevated in both the primary and metastatic SIC samples compared
to normal (5.71±3.1 and 3.01±1.4 vs. 0.49±0.19; p<0.05 and p<0.05.) [Figure 10A].
9g.ii. Tissue Microarray Analysis:
An examination of the ERα stained histospots from the 55 SIC patients on the TMA
demonstrated nuclear ERα expression. Differences between local (10.1±1) and
disseminated (12±0.5) SIC specimens as compared to normal (11±0.5) were not of
statistical significance. A comparison of the AQUA scores of patients with local vs.
disseminated disease was also statistically insignificant. (Mean AQUA Score: 10.1±1
vs. 12±0.5) [FIGURE 10B]

Fig. 10. Graphical presentation of Q-RT-PCR and AQUA Analysis for ERalpha in Small
Intestinal Carcinoids. (A) Mean mRNA expression levels varied between normal mucosa (0.49±0.19)
and primary (5.71±3.1) and metastatic (3.01±1.4) small intestinal carcinoid samples. These changes
were of statistical significance (#p<0.05, #p<0.05). (B) Mean protein expression levels between
primary tumors samples of patients with local (12±0.5) or disseminated disease (10.1±1) vs. normal
small intestinal mucosa (11±0.5) did not vary significantly and were not of statistical significance. NS=
not significant.
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9h. TFF1 in Small Intestinal Carcinoids:
9h.i. Q-RT-PCR Analysis:
The investigation of TFF1 revealed decreased message levels in primary and metastatic
SIC samples compared to normal (0.005±0.002 and 0.0059±0.0018 vs. 0.86±0.21;
p=0.05 and p=0.05). [FIGURE 11A]
9h.ii. Tissue Microarray Analysis:
An examination of the TFF1 stained histospots from the 55 SIC patients on the TMA
demonstrated TTF1 expression. Differences in local (83±5) and disseminated (75±4) SIC
specimens as compared to normal (98±6) were of statistical significance (p=0.05,
p<0.05). A comparison of the AQUA scores in the tumor specimens of patients with
local vs. disseminated disease (Mean AQUA Score: 83±5 vs. 75±4) were not of statistical
significance. [FIGURE 11B]

Fig. 11. Graphical presentation of Q-RT-PCR and AQUA Analysis for TFF1 in Small Intestinal
Carcinoids. (A) Mean mRNA expression levels decreased substantially in both primary (0.005±0.002)
and metastatic (0.0059±0.0018) small intestinal carcinoid tumor samples compared to the levels found
in normal small intestinal mucosa (0.86±0.21). These changes were of statistical significance
(*p=0.05, *p=0.05). (B) Mean protein expression levels were also decreased in primary tumor samples
of patients with local (83±5) or disseminated disease (75±4) compared to normal small intestinal
mucosa (98±6). These changes were also of statistical significance (*p=0.05, #p<0.05).
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9i. Analysis of the MTA1 Promoter Region:
The MTA1 promoter region contains c-Myc, c-Fos/c-Jun, c-Myb, and SP1 transcription
response element site in addition to two CpG methylation islands. [Figure 12]

LEGEND:
Transcription Factor Response Elements:
SP1……GGGCGG
c-Myc/Max……CACGTG
c-Fos/c-Jun……TGACTCA and TGAGTAA
GATA……AGATA and TGATA

c-MYB……TAACGG
TATA Box……TATA
CpG Island Region……CG
Start Codon……ATG
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9j. Isolation of the MTA1 Promoter Region:
We attempted to isolate the MTA1 promoter region for future studies in promoter
methylation patterns. Attempts to isolate the MTA1 promoter region were unsuccessful.
Troubleshooting efforts included changes in the annealing temperature, use of thermal
cycler touchdown mode, and changes in MgCl2 concentrations (1.5 mM vs. 2.5 mM).
Although the approaches resulted in the identification of correctly sized bands,
sequencing (W.M. Keck DNA Sequencing Facility) of these bands demonstrated that
they were non-specific products.

10. DISCUSSION
10a. The Presence of MTA1 in SIC: MTA1 as a Marker of SIC Malignancy
In both the Q-RT-PCR and AQUA studies, MTA1 expression was present and
increased as the tissue progressed from normal to primary tumor to metastatic tissue.
These results concur with previous reports of increased MTA1 levels and the association
with a more aggressive tumor phenotype (12, 13, 159). MTA1 may be a marker of SIC
malignancy.
10b. The Presence of HDAC2 in SIC: HDAC2 as a Marker of SIC Malignancy
In both the Q-RT-PCR and AQUA studies, HDAC2 expression was present and
increased in tumor tissue as compared to normal small intestinal mucosa. These results
concur with previously established data in gastric cancer (5). Increased expression of
HDAC2 may be a marker of SIC malignancy.
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10c. MTA1 Functionality in SIC
A comparison of MTA1 and TFF1 mRNA expression in our SIC series reveals an
inverse relationship. According to Mazumdar et al.’s model in the breast, MTA1 should
affect the expression of genes under the control of EREs. Our data displays a functional
role for MTA1 since with its overexpression, there is a concomitant decrease in TFF1
expression.
TFF1 is a protein product whose gene transcription is under the influence of
estrogen (187, 188). Wang et al. previously reported TFF1 immunoreactivity in ileal
carcinoids (192). The mRNA analysis of the TFF1 gene demonstrated dramatic decrease
in expression levels. In both the primary and metastatic tissue samples, TFF1 expression
was minimal. AQUA analysis also revealed decreased TFF1 protein expression in
primary and metastatic tissue. The slight discrepancy in the magnitude of transcript vs.
protein expression may indicate the presence of other factors affecting the ultimate
translation of the gene. When comparing TFF1 expression to ERα expression, one would
expect a direct relationship between the two proteins. In our study, such a relationship
does not exist. TFF1 mRNA expression did not increase in primary tumor specimens
which had a notable increase in ERα mRNA expression. Our data is converse to
previously established data that shows a direct relationship between ERα expression and
TFF1 (192). This may suggest the existence of estrogen-independent pathways or of
interfering pathways affecting TFF1 expression. The interfering agent may, in fact, be
MTA1, the suppressor of genes under the control of EREs. These data suggest MTA1
functionality in SIC as the expression of TFF1, a gene under the control of ERE, is
decreased in the presence of MTA1 upregulation.
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10d. HDAC2 Functionality in SIC
While demonstrating the presence of HDAC2 in SIC, the functionality of the
enzyme is of even greater importance. The results of the HDAC activity assay with
colorimetric histone deacetylate lysyl substrate indicate a significant increase in enzyme
activity in SICs as compared to normal mucosa. The addition of Trichostatin A greatly
reduced HDAC activity in both normal and tumor specimens. As in other cancers (146,
148), HDAC inhibitors may be a therapeutic intervention in SIC treatment.
The AQUA analysis of the acetylation status of Histone 2B (H2B) provides
further evidence of HDAC2 functionality in SIC. Acetylated H2B was significantly
decreased in SIC and their metastases as compared to normal mucosa. An examination of
the acetylated to non-acetylated H2B ratios in normal and carcinoid tissues further
suggests a role for histone deacetylation in SIC tumor progression.
10e. ERα and HER2 in SIC
In previous studies, the existence of ERα in carcinoid tumors was a point of
contention. Chan et al. demonstrated hypermethylation of the ERα promoter region in
neuroendocrine tumors (185). In our study, we have demonstrated both ERα message and
protein expression in SICs. While levels of protein staining amongst normal, primary,
and liver metastatic SIC tissue did not vary significantly, the general pattern in both the
Q-RT-PCR and AQUA analyses revealed downward trend in expression levels. This is
similar to the ERα message expression pattern in breast cancer, where the presence of
estrogen receptors typically indicates slower-growing tumors that may be amenable to
hormonal manipulation (180). Focusing on the nuclear ERα protein expression, the lack
of significant variation in protein expression in normal and tumor specimens may indicate
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a lack of ERα importance as a prognostic indicator in SIC patients. This also diminishes
support for the use of ERα-targeting therapies such as Tamoxifen in the treatment of this
tumor type. In addition, MTA1 and the estrogen receptor were previously shown to have
an inverse relationship in the study of hepatocellular carcinoma, suggesting a possible
regulatory role for MTA1 (12). This relationship was not found in our study of the SICs.
This may perhaps be due to the lack of variance in ERα expression and thus,
underscoring the notion that ERα may be of little or no significance in SIC tumorigenesis.
Amplification of HER2/neu, a protooncogene related to the epidermal growth
factor receptor (193), has prognostic significance in patients with breast cancer.(178)
HER2/neu protein expression using conventional staining dilutions (1:10,000) has not
been identified in GI carcinoids (194). At higher antibody concentrations, HER2 has been
identified in 31% of carcinoid tumors (195). In our investigation of SIC tumors, HER2
mRNA expression was low compared to normal. There was a small decrease in
expression levels when comparing primary to metastatic tumor and a similar pattern was
seen in the AQUA analysis of HER2. This receptor is present, but not overexpressed in
SICs. Of note is the fact that is was necessary to use a higher level of antibody
concentration than the amount normally utilized in the TMA analysis of breast tissue.
This requisite for our study suggests that HER2 may not be of biological significance in
SIC. Combining this notion with our current understanding of Herceptin as a HER2targeted therapy, it becomes apparent that this, too, may not be a viable option for small
intestinal carcinoid therapy. In addition, many breast studies, in both clinical and basic
science settings, have drawn an inverse relationship between HER2 and ERα (196-198).
In our study, the existence of such a relationship was impossible to determine given the
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lack of variation in expression levels of these proteins between normal and tumor
samples.
Since HER2 and ERα gene and protein expression appears to be of little
importance in SIC, we propose that MTA1, while a potential marker of SIC malignancy,
is not under the control of HER2, as seen in the breast model (8). It may, however, be
functional in SIC as it may induce the repression of TFF1, suggested by the inverse
relationship between the two.
10f. Exploration of the Hergulin/HER2 pathway as a Means of MTA1 Expressional
Control in SICs
In addition to exploring the potential presence of epigenetic factors in SIC
tumorigenesis, we sought to define pathways of upregulation of the MTA1 complex. In
defining these pathways, it was of paramount importance to delineate the inducers of
MTA1 expression, hence the induction of malignant progression.
As proposed by Mazumdar et al. (8), heregulin, by binding to the HER2/neu
receptor, can induce MTA1 expression. The Q-RT-PCR and AQUA studies confirmed
the presence of MTA1 in normal, primary tumor, and metastatic tissues, indicating a
concomitant increase in gene and protein expression levels as the neoplastic process
evolved. We, however, failed to detect a role for HER2 in carcinoid development.
Message levels decreased in the progression from normal to tumor and metastatic tissue.
Alterations in protein expression, however, failed to support a role for HER2 in SIC
development. The MTA1 and HER2 data were incongruent, indicating the presence of
other means of transcriptional activation of MTA1 in SIC.
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10g. Exploration of Other Mechanisms of MTA1 Expression Control
The negative HER2 findings led to the exploration of the promoter region of the
MTA1 gene. Through use of the Ensembl® v36 genome database and MTA1 promoter
region analysis, we identified nucleotide patterns associated with transcription factor
response elements including SP1 (GGGCGG), c-myc/Max (CACGTG), c-Fos/c-Jun
(TGACTCA & TGAGTAA). In addition, we observed 2 CpG Island rich areas proximal
to the start codon (ATG).
10h. CpG Island Methylation as a Means of Control of MTA1 Expression in SIC
CpG Islands are typically sites of DNA methylation- a means of epigenetic
control of gene expression. The aberrant demethylation of the MTA1 promoter region
may be the cause of this gene’s upregulation in SIC and their metastases. Despite
attempts to adjust annealing temperatures and MgCl2 concentrations, we were
unsuccessful in our efforts to amplify the promoter region. It is possible that the samples
(gy1-4) were degraded, but this is unlikely due to the fact that other genes were isolated
from these samples (DATA NOT SHOWN).
After the isolation of the promoter region, future investigations would have
involved methylation-specific PCR of primary SIC, their metastases, and normal small
intestinal tissue. The establishment of methylation patterns in the MTA1 promoter region
could unveil the presence of aberrant demethylation, resulting in MTA1 overexpression.
To further explore the potential role of aberrant demethylation in MTA1 upregulation,
efforts should also be directed towards the analysis of demethylating enzymes such as
DNA demethylase (199). Aberrant demethylation has been found in ovarian cancer to

58

induce HER2 and survivin expression (200). Similar demethylating events may occur in
SICs.
Efforts are currently being redirected towards the development of a GI carcinoid
cell line with which functional in vitro studies on cell growth and motility may be
performed. In addition, cell transformation and deletional analyses will be possible.

11. CONCLUSION
The impetus behind this project was the requirement to include molecular
analyses in carcinoid tumor classification. Today’s tumor classification practices
incorporate gross pathological, histological, clinical, and biochemical criteria. While
helpful, the current system fails to provide a means of accurate diagnosis,
prognostication, and assessment of optimal treatment plan. Molecular analysis should
facilitate the improved classification of carcinoids, as well as provide a means to
delineate the molecular pathways involved in the tumorigenesis of SIC.
The data from this investigation have demonstrated the presence and functionality
of both HDAC2 and MTA1 in small intestinal carcinoids. These results support the
potential role of aberrant epigenetic modulation in the development and evolution of SICs.
The overexpression of HDAC2 and MTA1 has been identified in small intestinal
carcinoids and suggest novel markers for carcinoid malignancy. Identification of HDAC2
functionality in SIC suggests the potential therapeutic use of HDAC inhibitors in SIC
patients.
This study has also provided genetic and proteomic evidence of the lack of
involvement of ERα and HER2 in SIC, a previous topic of debate. Low message and
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protein levels of both ERα and HER2 indicate the lack of a role for these receptors in
small intestinal carcinoid. In addition, such results underscore the reduced potential for
HER2- or ERα- targeted therapy to eradicate carcinoid tumors. The discovery of the
absence of a relationship between HER2 and MTA1 in our small intestinal carcinoid
series (unlike the direct relationship in the breast model) indicates that other modes of
MTA1 expressional control may require to be elucidated. The schematic below provides
a visual summary of the MTA1 complex pathway.
Other
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Fig. 13. Schematic representing possible MTA1 pathway in SICs. Other regulators may include promoter
methylation and c-MYC.

Future efforts should be directed specifically towards the relationship between cMyc and MTA1 and HDAC2 expression in SICs. C-Myc has already been implicated in
the overexpression of MTA1 and HDAC2 in various cancers(6, 170). Studies have
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already shown the impact of c-Myc inhibition in cell cycle progression(201, 202). The
elucidation of c-Myc’s role in SICs in association with MTA1 and HDAC2 will provide
further delineation of SIC pathogenesis as well as the development of new therapeutic
approaches.
In sum, molecular analysis of SICs has great potential in changing the diagnostic
and therapeutic landscape of these rare tumor entities.
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